SCHEMBL112412

SCHEMBL112412

CCOC(=O)C(=O)C(Br)CC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
TRPA1 O75762 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
GLO1 Q04760 1/20 0.39
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 1/20 0.38
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
EGLN1 Q9GZT9 1/20 0.36
MAPT P10636 3/20 0.35
CYP2D6 P10635 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ZDHHC7 Q9NXF8 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3828447 0.83 ZDHHC7 (0.40) ALDH1A1TRPA1NPSR1GLO1LMNA
SCHEMBL6337519 0.81 ALDH1A1 (0.36) ALDH1A1TRPA1NPSR1GLO1LMNA
SCHEMBL26984770 0.81 ALDH1A1 (0.36) ALDH1A1TRPA1NPSR1GLO1LMNA
SCHEMBL3648200 0.81 EGLN1 (0.41) ALDH1A1TRPA1NPSR1GLO1LMNA
SCHEMBL6337398 0.79 ZDHHC7 (0.50) ALDH1A1TRPA1NPSR1GLO1LMNA
SCHEMBL2824321 0.79 ALDH1A1 (0.47) ALDH1A1NPSR1LMNAHSD17B10TSHR
SCHEMBL15110273 0.79 ALDH1A1 (0.41) ALDH1A1TSHREGLN1ZDHHC7KMT2A
SCHEMBL114311 0.79 ALDH1A1 (0.42) ALDH1A1TRPA1NPSR1GLO1LMNA
SCHEMBL1732642 0.78
SCHEMBL1732696 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121423-B1 TETRAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2026-04-29 EP disclosed
EP-4695242-A1 NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF Meta Pharmaceuticals (HK) Limited (HK) 2026-02-18 EP disclosed
EP-4121429-B1 CONDENSED PYRIDINE DERIVATIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS MERCK PATENT GMBH (DE) 2025-08-13 EP disclosed
WO-2025151402-A1 THIAZOLE TRPML1 AGONISTS AND USES THEREOF LIBRA THERAPEUTICS, INC. (US) 2025-07-17 WO disclosed
EP-4551571-A1 OXAZOLE TRPML1 AGONISTS AND USES THEREOF Libra Therapeutics, Inc. (US) 2025-05-14 EP disclosed
CN-119790050-A Oxazole TRPML1 agonists and uses thereof 利布拉医疗公司 2025-04-08 CN disclosed
CN-115335371-B Tetrazole derivatives 默克专利股份公司 2024-12-27 CN disclosed
US-20240382468-A2 TETRAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2024-11-21 US disclosed
WO-2024212907-A1 NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF META PHARMACEUTICALS (HK) LIMITED (CN) 2024-10-17 WO disclosed
CN-114630822-B Biaryl dihydroorotate acid dehydrogenase inhibitors 詹森生物科技公司 2024-10-01 CN disclosed
US-20040063691-A1 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION 2004-04-01 US disclosed
US-20030207885-A1 Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands NEUROGEN CORPORATION 2003-11-06 US disclosed
EP-1343772-A1 THIA- AND OXAZOLES AND THEIR USE AS PPARS ACTIVATORS GLAXO GROUP LIMITED (GB) 2003-09-17 EP disclosed
WO-2003040107-A1 IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2003-05-15 WO disclosed
WO-2003006471-A1 HETEROARYL SUBSTITUTED FUSED BICYCLIC HETEROARYL COMPOUNDS AS GABAA RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2003-01-23 WO disclosed
US-6498174-B1 AGONISTS TO PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; MODULATING BLOOD GLUCOSE AND LIPID LEVELS; REDUCING DYSLIPIDEMIA AND HYPERINSULINEMIA ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE OR METABOLIC SYNDROME SMITHKLINE BEECHAM CORPORATION 2002-12-24 US disclosed
WO-2002050048-A1 THIA- AND OXAZOLES AND THEIR USE AS PPARS ACTIVATORS GLAXO GROUP LIMITED (GB) 2002-06-27 WO disclosed
CN-1321152-A Substituted oxazole and thiazole derivatives as hPPAR gamma and hPPAR alpha activators GLAXO GROUP LTD (GB) 2001-11-07 CN disclosed
EP-1102757-A1 SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS GLAXO GROUP LIMITED (GB) 2001-05-30 EP disclosed
WO-2000008002-A1 SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS GLAXO GROUP LIMITED (GB) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382468-A2 TETRAZOLE DERIVATIVES VHL, BRCA1, POT1 ALDH1A1 1752/4885TRPA1 4699/4885NPSR1 4678/4885
US-20040063691-A1 Preparation and use of imidazole derivatives for treatment of obesity GPR119, GIPR, PGC ALDH1A1 2202/4885TRPA1 1399/4885NPSR1 597/4885
US-20030207885-A1 Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands GABRA5, GABRA2, GABBR1 ALDH1A1 553/4885TRPA1 753/4885NPSR1 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.